不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
brexu-cel 治疗复发/难治性 B 细胞急性淋巴细胞白血病和套细胞淋巴瘤的成本效果研究：一项系统综述
英文原题：Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review.
查看英文原题
Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
Brexu-cel 在所有 CEA 研究和苏格兰的一份 HTA 报告中均被认为具有成本效益，但其他 HTA 机构报告称 brexu-cel 用于 R/R ALL 和 R/R MCL 的成本效益存在不确定性。
研究思路结论见上方概要
背景
本系统综述旨在探讨brexu-cel在不同国际司法管辖区中成本效益的现有证据。
方法
截至2024年6月24日，对Embase、Medline、Econlit、Web of Science、Scopus、灰色文献中的文章以及HTA报告的手动检索进行了系统检索。纳入评估brexu-cel在复发/难治性急性淋巴细胞白血病（R/R ALL）和套细胞淋巴瘤（R/R MCL）中成本效益的原始英文文章和来自不同国家的报告。本综述已在Open Science Framework（OSF）注册中心注册。
结果
在149条记录中，经标题和摘要筛选后，有22篇文章进行了全文审查，其中5篇符合纳入标准，同时还有来自澳大利亚、加拿大、苏格兰和英格兰的7份HTA报告。CEA研究来自美国、英格兰、加拿大和意大利，视角各异，主要采用分区生存模型和终身时间跨度。brexu-cel的模型输入数据来自ZUMA-2和ZUMA-3试验，比较数据来自各自的试验或文献。
展开英文摘要原文
METHODS
A systematic search of articles on Embase, Medline, Econlit, Web of Science, Scopus, gray literature, and a manual search of HTA reports was done until 24 June 2024. Original English articles and reports from different countries assessing the cost-effectiveness of brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) and mantle cell lymphoma (R/R MCL) were included. This review was registered in the Open Science Framework (OSF) registry.
RESULTS
Of the 149 records, 22 articles underwent full-text review after the title and abstract screening, five met the inclusion criteria along with seven HTA reports from Australia, Canada, Scotland, and England. The CEA studies were from the US, England, Canada, and Italy, with varying perspectives, mainly adopting a partitioned survival model and lifetime horizons. The model input data from the ZUMA-2 and ZUMA-3 trials were used for brexu-cel, with comparisons from their respective trials or literature.
CONCLUSION
Brexu-cel was found cost-effective in all the CEA studies and an HTA report from Scotland, but the other HTA agencies reported uncertainties around the cost-effectiveness of brexu-cel for R/R ALL and R/R MCL. REGISTRATION: Open Science Framework. (Reg doi: https://doi.org/10.17605/OSF.IO/JZU6Y).
论文信息
- 作者
- Khatiwada AP、Kamel AMA、Chaiyakunapruk N、Ngorsuraches S
- 单位
- Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University, Auburn, AL, USA.United States
- 文献类型
- 综述
- 期刊
- Expert review of pharmacoeconomics & outcomes research2024 Dec 13
- 原文标识
- PubMed 39632795 · DOI 10.1080/14737167.2024.2438631